Sabirnetug - Acumen Pharmaceuticals
Alternative Names: ACU-193; Alzheimer's disease immunotherapy - Acumen Pharmaceuticals; anti-ADDL antibodies; HuC-091Latest Information Update: 25 Jul 2024
At a glance
- Originator Northwestern University
- Developer Acumen Pharmaceuticals
- Class Antidementias; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Amyloid beta-protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Alzheimer's disease
Most Recent Events
- 25 Jun 2024 Phase-I clinical trials in Alzheimer's disease (In volunteers) in USA (SC) (NCT06511570)
- 25 Jun 2024 Acumen Pharmaceuticals initiates a phase I trial for Alzheimer's disease (In volunteers) in USA (IV) (NCT06511570)
- 12 Apr 2024 Updated efficacy data from the phase I INTERCEPT-AD trial in Alzheimer's disease presented at the 76th Annual Meeting of the American Academy of Neurology (AAN-2024)